Case series of acute arthritis during COVID-19 admission

The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has changed life significantly worldwide. Rheumatologists also had to get used to the new context, prioritising remote over in-person consultations or solving doubts and giving advice to our immunocompromised patients. Besides, international collaborations have provided opinions concerning decisions that may affect people with rheumatic diseases; for instance, a major provision and use of hydroxychloroquine for COVID-19 might lead to a shortage for patients with lupus or rheumatoid arthritis, as Graef and colleagues point out in their recent viewpoint.1

In areas of higher impact of the outbreak, as occurred in Spain, some of us have collaborated with colleagues from respiratory medicine and infectious diseases within multidisciplinary teams to face COVID-19. A collateral advantage has been the opportunity to evaluate the musculoskeletal manifestations of COVID-19, to date just described as non-specific joint pain,2 while no cases of arthritis have been reported at diagnosis or during the infection.

Up to 30 April 2020, in Alicante General University Hospital, 306 patients with proven COVID-19 have been admitted. Eighty-one (26.4%) complained of muscle and joint pain at presentation. No patient had evident arthritis at admission, but four (1.3%) developed acute arthritis during hospitalisation. Here we present their relevant features (table 1).

All patients had a history of recurrent acute arthritis in different locations (knee, first metatarsophalangeal joint or ankle). Three had a previous diagnosis of gout, but presence of crystals was only studied in one (patient 4). Treatment with allopurinol was variable, and none received daily colchicine.

COVID-19 was diagnosed in three of them by reverse transcriptase PCR (RT-PCR) for SARS-CoV-2 in nasopharyngeal aspirates. Patient 4 was repeatedly tested negative in RT-PCR but confirmed by SARS-CoV-2 IgM and IgG detection.3 All patients received hydroxychloroquine; tocilizumab (in three cases) and pulses of methylprednisolone (in two cases) were necessary because of severe pneumonia. Interestingly, all episodes of acute arthritis occurred despite those treatments. The synovial fluid analysis allowed definitive diagnoses, and flares successfully resolved with our standard approach (corticosteroids and colchicine).

Joint and muscle pain are common in acute viral illnesses. It also seems to occur in COVID-19,2 but the occurrence of arthritis has not been confirmed to date. Here we report four cases of acute arthritis developed during COVID-19 admissions, all due to crystal-proven flares (gout and calcium pyrophosphate disease). It remains essential to check every arthritis by polarised microscopy, even during the SARS-CoV-2 pandemic. Viral detection in synovial fluid had not been tested to date, though reported low rates of viraemia make it unlikely.4 5 We managed to have synovial fluids tested for SARS-CoV-2 by RT-PCR in the three cases, being all negative.

Rheumatologists, at multiple levels and from different perspectives,1 may be of great value during the COVID-19 pandemic.

Maria-del-Carmen López-González,1 Maria Luisa Peral-Garrido,1 Irene Calabuig,2 Ernesto Tovar-Sugañés,1 Vega Jovani,3 Pilar Bernabeu, Raquel García-Sevilla,4 Jose-Manuel León-Ramirez,4 Oscar Moreno-Perez,5,6 Vicente Boix,5,6 Joan Gil,6 Esperanza Merino,7 Paloma Vela,6,8 Mariano Andrés,1,6,8

1. Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain
2. Reumatología, Hospital General Universitario de Alicante, Alicante, Spain
3. Neumología, Hospital General Universitario de Alicante, Alicante, Spain
4. Medicina Clínica, Universidad Miguel Hernandez de Elche, Elche, Spain
5. Unidad de Enfermedades Infecciosas, Hospital General Universitario de Alicante, Alicante, Spain
6. Medicina Clínica, Universidad Miguel Hernandez de Elche, Elche, Spain
7. Unidad de Enfermedades Infecciosas, Hospital General Universitario de Alicante, Alicante, Spain
8. Rheumatology Department, Hospital General Universitario de Alicante, Alicante, Spain

Correspondence Dr Mariano Andrés, Sección de Reumatología, Hospital General Universitario de Alicante, Alicante 03010, Spain; drmarianoandres@gmail.com

Contributors All authors took part in data acquisition and analysis. MdCL-G and MA wrote the first draft. All authors approved the final version of the manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Table 1 Clinical features and management of four patients with acute arthritis during COVID-19 admission

<table>
<thead>
<tr>
<th>Patient</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)/gender</td>
<td>71/male</td>
<td>61/male</td>
<td>64/male</td>
<td>45/male</td>
</tr>
<tr>
<td>Days from COVID-19 symptom onset to arthritis</td>
<td>8</td>
<td>19</td>
<td>8</td>
<td>27</td>
</tr>
<tr>
<td>Days from admission to arthritis</td>
<td>3</td>
<td>17</td>
<td>7</td>
<td>21</td>
</tr>
<tr>
<td>COVID-19 management</td>
<td>Hydroxychloroquine</td>
<td>Hydroxychloroquine, azithromycin, tocilizumab, pulses of methylprednisolone</td>
<td>Hydroxychloroquine, azithromycin, lopinavir–ritonavir, tocilizumab</td>
<td>Hydroxychloroquine, tocilizumab, pulses of methylprednisolone</td>
</tr>
<tr>
<td>Known inflammatory arthritis</td>
<td>Gout, on allopurinol 100 mg/day</td>
<td>Gout, on allopurinol 100 mg/day (irregular)</td>
<td>Previous recurrent arthritis, not studied or treated</td>
<td>Crystal-proven gout, on allopurinol 300 mg/day</td>
</tr>
<tr>
<td>Allopurinol stopped during admission</td>
<td>No</td>
<td>No</td>
<td>–</td>
<td>Yes</td>
</tr>
<tr>
<td>Involved joints</td>
<td>First MTP</td>
<td>Ankle</td>
<td>Both knees</td>
<td>Knee and ankle</td>
</tr>
<tr>
<td>SF characteristics</td>
<td>ND</td>
<td>Glucose: 38 mg/dL Leucocytes: 137 534 μL (95% PMN)</td>
<td>Glucose: 94 mg/dL Leucocytes: 1362 μL (77% PMN)</td>
<td>Glucose: 38 mg/dL Leucocytes: 39 065 μL (96% PMN)</td>
</tr>
<tr>
<td>Polarisated light microscopy</td>
<td>MSU crystals</td>
<td>MSU crystals</td>
<td>CPP crystals</td>
<td>MSU crystals</td>
</tr>
<tr>
<td>SF culture</td>
<td>ND</td>
<td>Negative</td>
<td>Negative</td>
<td>Negative</td>
</tr>
<tr>
<td>SF RT-PCR for SARS-CoV-2</td>
<td>ND</td>
<td>Negative</td>
<td>Negative</td>
<td>Negative</td>
</tr>
</tbody>
</table>

CPP, calcium pyrophosphate; MSU, monosodium urate; MTP, metatarsophalangeal; ND, not done (insufficient amount of fluid was obtained); PMN, polymorphonuclear; RT-PCR, reverse transcriptase PCR; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SF, synovial fluid.
Correspondence

Competing interests MA declares speaking fees and research grants from Grunenthal, Menarini and Horizon.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; internally peer reviewed.

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.


Received 7 May 2020
Accepted 12 May 2020
Published Online First 29 May 2020

> http://dx.doi.org/10.1136/annrheumdis-2020-217989

ORCID iDs
Irene Calabuig http://orcid.org/0000-0002-8755-0149
Mariano Andrés http://orcid.org/0000-0002-0219-9055

REFERENCES